Phenytoin application in radiation induced dermatitis

Prophylactic & therapeutic effects of topical phenytoin administration on radiation induced dermatitis in breast cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012070710205N1

Enrollment

Registered

2013-06-01

Start date

2012-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention (Phenytoin topical ointment): Patients undergoing radiotherapy will receive Phenytoin ointment BD, for 25 sessions (5 days/week). Intervention 2: Control (Placebo/ ointmen

Treatment - Drugs

Placebo

Intervention (Phenytoin topical ointment): Patients undergoing radiotherapy will receive Phenytoin ointment BD, for 25 sessions (5 days/week)

Control (Placebo/ ointment base): Patients undergoing radiotherapy will receive petrolatum ointment BD, for 25 sessions (5 days/week)

Eligibility

Sex/Gender

Female

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with first occurrence of breast cancer Exclusion criteria: Patients with concurrent chemoradiation; diabetes; collagen-vascular diseases; history of radiotherapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Dermatitis. Timepoint: Weekly. Method of measurement: According to RTOG scoring system.	—

Secondary

Measure	Time frame
Local adverse reactions. Timepoint: weekly. Method of measurement: physical exam.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEbrahim Zabihi

Vice Chancellor for Research and technology, Babol University of Medical Sciences

e_zabihi@yahoo.com+98 11121995915

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026